Skip to main content
SpringerLink
Log in

Budget Impact Analysis of Oral Fisiogen Ferro Forte® versus Intravenous Iron for the Management of Iron Deficiency in Chronic Kidney Disease in Spain

  • Original Research Article
  • Published:
Clinical Drug Investigation Aims and scope Submit manuscript

Abstract

Background

Iron deficiency is a frequent complication of chronic kidney disease (CKD) that is associated with a decrease in the quality of life of patients and an increase in the risk of other clinical complications. Iron therapy represents one of the fundamentals of patients with CKD. Sucrosomial® oral iron allows Fisiogen Ferro Forte® to be used in all patients who are intolerant to treatment by the oral route of administration, or who present with malabsorption of conventional oral iron preparations.

Objective

The main objective of this study was to assess the economic impact of the oral iron Fisiogen Ferro Forte® for the management of iron deficiency in CKD patients in Spain.

Methods

A 4-year budget impact model was developed for the period 2017–2020 for CKD patients with iron deficiency who were candidates for intravenous iron due to a lack of response to oral iron, from the perspective of the Spanish healthcare system. Three subgroups of CKD patients were included in the analysis: predialysis, peritoneal dialysis, and post-transplant. The intravenous iron formulations Ferinject®, Venofer®, and Feriv® were considered appropriate comparators to be used in the model. National data on the prevalence of CKD for the three subgroups of patients were obtained from the literature, and input data on drug utilization and outpatient hospitalizations associated with iron administration were obtained by consulting nephrologists. Nephrology experts were also asked about resources used during medical visits and monitoring tests. Based on the unit costs for each iron therapy and the resources used, the total treatment cost per patient associated with each product was obtained to estimate the global budget impact of increasing the use of Fisiogen Ferro Forte®.

Results

The average annual budget savings due to an increase in Fisiogen Ferro Forte® and a decrease in intravenous iron have been estimated at €398,685, €180,937, and €195,842 over 4 years for the predialysis, peritoneal dialysis, and post-transplant groups, respectively.

Conclusions

The increase in the use of Fisiogen Ferro Forte® leads to overall budget savings of €775,464 for the Spanish National Health Service over 4 years.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Fig. 1

Similar content being viewed by others

References

  1. Otero A, De Francisco A, Gayoso P, García F. Prevalence of chronic renal disease in Spain: results of the EPIRCE study. Nefrologia. 2010;30(1):78–86.

    PubMed  Google Scholar 

  2. Fehr T, Ammann P, Garzoni D, Korte W, Fierz W, Rickli H, et al. Interpretation of erythropoietin levels in patients with various degrees of renal insufficiency and anemia. Kidney Int. 2004;66(3):1206–11.

    Article  CAS  Google Scholar 

  3. Locatelli F, Aljama P, Bárány P, Canaud B, Carrera F, Eckardt KU, et al. European Best Practice Guidelines Working Group. European best practice guidelines for the management of anaemia in patients with chronic renal failure. Revised. Nephrol Dial Transpl. 2004;19(Suppl 2):1–47.

    Google Scholar 

  4. Gorostidi M, Santamaría R, Alcázar R, Fernández-Fresnedo G, Galcerán JM, Goicoechea M, et al. Documento de la Sociedad Española de Nefrología sobre las guías KDIGO para la evaluación y el tratamiento de la enfermedad renal crónica. Nefrología (Madrid). 2014;34(3):302–16.

    Google Scholar 

  5. Brilli E, Lipinski P, Barnadas R, Camacho M, Fabiano A, Giordano G, et al. Sucrosomial iron absorption involve M cells interaction. Blood. 2017;130(Suppl 1):2217.

    Google Scholar 

  6. Fabiano A, Brilli E, Fogli S, Beconcini D, Carpi S, Tarantino G, et al. Sucrosomial® iron absorption studied by in vitro and ex vivo models. Eur J Pharm Sci. 2018;111:425–31.

    Article  CAS  Google Scholar 

  7. Parisi F, Berti C, Mandò C, Martinelli A, Mazzali C, Cetin I. Effects of different regimens of iron prophylaxis on maternal iron status and pregnancy outcome: a randomized control trial. J Matern Fetal Neonatal Med. 2017;30(15):1787–92.

    Article  CAS  Google Scholar 

  8. Mafodda A, Giuffrida D, Prestifilippo A, Azzarello D, Giannicola R, Mare M, et al. Oral sucrosomial iron versus intravenous iron in anemic cancer patients without iron deficiency receiving darbepoetin alfa: a pilot study. Supp Care Cancer. 2017;25(9):2779–86.

    Article  Google Scholar 

  9. Giordano G, Mondello P, Tambaro R, Perrotta N, D’amico F, D’aveta A, et al. Biosimilar epoetin α is as effective as originator epoetin-α plus liposomal iron (Sideral®), vitamin B12 and folates in patients with refractory anemia: a retrospective real-life approach. Mol Clin Oncol. 2015;3(4):781–4.

    Article  CAS  Google Scholar 

  10. Pisani A, Riccio E, Sabbatini M, Andreucci M, Del Rio A, Visciano B. Effect of oral liposomal iron versus intravenous iron for treatment of iron deficiency anaemia in CKD patients: a randomized trial. Nephrol Dial Transplant. 2014;30(4):645–52.

    Article  Google Scholar 

  11. Ciudin A, Simó-Servat O, Balibrea JM, Vilallonga R, Hernandez C, Simó R, et al. Response to oral sucrosomial iron supplementation in patients undergoing bariatric surgery. The BARI-FER study. Endocrinol Diabetes Nutr. 2018;65:17–20.

    Article  Google Scholar 

  12. Rubio-Terrés C, López ÁF, Montero AF, Vega JM, Castelao AM, Gisbert JP, et al. Análisis farmacoeconómico del tratamiento de la deficiencia de hierro con hierro carboximaltosa (Ferinject®) en España. PharmacoEcon Span Res Articles. 2010;7(3):109–17.

    Article  Google Scholar 

  13. Martín JE. Análisis coste-beneficio de la utilización de Ferinject. 2014.

  14. Egocheaga MI, Lobos JM, Guissasola FA, Alcázar R, Orte L, Parra EG, et al. Documento de consenso sobre la enfermedad renal crónica. Sociedad Española de Nefrología (SEN). Sociedad Española de Medicina de Familia y Comunitaria (semFYC). Barcelona: semFYC Ediciones; 2007.

  15. Escobar EM, de Enfermos Renales RE. Registro Español de Enfermos Renales. Informe 2013 y evolución 2007–2013. Nefrología. 2016;36(2):97–120.

    Article  Google Scholar 

  16. Instituto Nacional de Estadístico (INE) Proyecciones de población a corto plazo. 2011–2021. http://www.ine.es/jaxi/menu.do?type=pcaxis&path=%2Ft20%2Fp269%2F2011-2021&file=pcaxis&L=. Accessed 19 Dec 2017.

  17. Consejo General de Colegios Oficiales de Farmacéuticos. BOT plus web. 2012. https://botplusweb.portalfarma.com/. Accessed 12 Dec 2017.

  18. Orden 731/2013, de 6 de septiembre, del Consejero de Sanidad, por la que se fijan los precios públicos por la prestación de los servicios y actividades de naturaleza sanitaria de la Red de Centros de la Comunidad de Madrid. http://www.madrid.org/wleg/servlet/Servidor?opcion=VerHtml&nmnorma=8275&cdestado=P. Accessed Dec 2017.

  19. Llei 12/2015, de 29 de desembre, de mesures fiscals, de gestió administrativa i financera, i d’organització de la Generalitat de la Comunitat Valenciana. Available at: www.dogv.gva.es/datos/2015/12/31/pdf/2015_10410.pdf. Accessed Dec 2017.

Download references

Acknowledgements

The authors would like to thank the nephrology experts, Dr. Verónica Duarte and Dr. Aleix Cases, for their participation in this study.

Author information

Authors and Affiliations

  1. Department of Economics, Universitat de Barcelona, Diagonal 690, 08034, Barcelona, Spain

    Josep Darbà

  2. BCN Health Economics & Outcomes Research S.L., Barcelona, Spain

    Meritxell Ascanio

Authors
  1. Josep Darbà
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Meritxell Ascanio
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Josep Darbà.

Ethics declarations

Conflicts of interest

Josep Darbà is employed by the University of Barcelona, and Meritxell Ascanio is an employee of BCN Health Economics & Outcomes Research S.L., an independent contract health economic organization that has received research funding from Zambon.

Funding

This study was sponsored by Zambon.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Darbà, J., Ascanio, M. Budget Impact Analysis of Oral Fisiogen Ferro Forte® versus Intravenous Iron for the Management of Iron Deficiency in Chronic Kidney Disease in Spain. Clin Drug Investig 38, 801–811 (2018). https://doi.org/10.1007/s40261-018-0666-9

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40261-018-0666-9

Search

Navigation